Cabergoline in Metastatic Breast Cancer

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 11, 2013

Primary Completion Date

December 15, 2015

Study Completion Date

October 27, 2017

Conditions

Recurrent Breast CancerStage IV Breast Cancer

Interventions

DRUG

cabergoline

Given orally

Trial Locations (1)

Northwestern University, Chicago

All Listed Sponsors

collaborator

Lynn Sage Foundation

UNKNOWN

lead

Northwestern University

OTHER

NCT01730729 - Cabergoline in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter